Related Experiment Videos
Managing dyslipidemias: update on guidelines and pharmacotherapy
Robert P Paone1, Marialice Bennett
1Massachusetts College of Pharmacy and Health Sciences, Boston, USA.
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)
|September 26, 2002
Summary
New Adult Treatment Panel III (ATP III) guidelines for dyslipidemia impact millions, necessitating pharmacist involvement. Pharmacists play a key role in screening, treatment implementation, and ongoing management of high cholesterol patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacotherapy
- Public Health
Background:
- New Adult Treatment Panel III (ATP III) guidelines for dyslipidemia diagnosis and treatment are more stringent than previous recommendations.
- These updated guidelines identify a significant portion of the American population requiring intervention for lipid disorders.
Purpose of the Study:
- To highlight the substantial number of Americans needing therapeutic lifestyle changes and drug therapy for dyslipidemia based on ATP III.
- To emphasize the critical role of pharmacists in implementing these new, more stringent dyslipidemia guidelines.
Main Methods:
- Analysis of the impact of ATP III guidelines on the US population requiring lipid management.
- Identification of key pharmacist interventions in the care continuum for patients with dyslipidemias.
Main Results:
- An estimated 65 million Americans require therapeutic lifestyle changes for dyslipidemia.
- Of those, 36.5 million necessitate drug therapy according to ATP III criteria.
- Pharmacists are positioned to screen, assist treatment, and provide ongoing management for these patients.
Conclusions:
- Effective implementation of ATP III guidelines is crucial for managing widespread dyslipidemias.
- Pharmacists are essential healthcare providers capable of facilitating guideline adherence and improving patient outcomes for high cholesterol.